Immune response activation following hyperthermic intraperitoneal chemotherapy for peritoneal metastases: A pilot study

Table 1 Sample characteristics

	n	%
Males	3	50
Females	3	50
Appendiceal mucinous neoplasms - pseudomyxoma peritonei	4	67
Colon cancers	2	33
Age (yr)	55 (median)	48-71 (range)

Table 2 Immunological analysis: absolute values, cells/L

		Baseline						30 d after HIPEC
ID	Tumor type	CD3+	CD3+/CD4+ T helpe r	CD3+/CD8+ T cytotoxic	CD3-/CD56+ NK	CD19+ B lymphocytes	CD4/CD8 ratio	CD3+	CD3+/CD4+ T helper	CD3+/CD8+ T cytotoxic	CD3-/CD56+ NK	CD19+ B lymphocytes	CD4/CD8ratio
1	Colon	842	602	188	234	61	3	1335	835	409	501	78	2
2	PMP	970	505	473	238	129	1	487	300	187	57	68	2
3	PMP	1044	1500	1700	475	150	1	4477	2248	2179	576	488	1
4	Colon	1244	1075	158	44	230	7	1409	1095	290	116	148	4
5	PMP	1228	874	340	141	134	3	2304	1443	846	421	141	2
6	PMP	912	776	147	173	152	5	2002	1184	782	334	184	2

PMP: Pseudomyxoma peritonei; HIPEC: Hyperthermic intraperitoneal chemotherapy; NK: Natural killer.

Table 3 Immunological response: statistical analysis

	Mean (standard deviation) baseline	Median (interquartile range) baseline	Mean (standard deviation) 30 d after HIPEC	Median (interquartile range) 30 d after HIPEC	Unilateral paired Student t test	P value
CD3+	1040.0 (± 165.8)	1007.0 (912.0–1228.0)	2002.3 (± 1364.4)	1705.5 (1335.0–2304.0)	-1.75	0.07
CD3+/CD4+ T helper	888.7 (± 360.8)	825.0 (602.0–1075.0)	1184.2 (± 649.7)	1139.5 (835.0–1443.0)	-2.05	0.048
CD3+/CD8+ T cytotoxic	501.0 (± 600.9)	264.0 (158.0–473.0)	782.2 (± 733.6)	595.5 (290.0–846.0)	-2.05	0.048
CD3-/CD56+ NK	217.5 (± 144.9)	203.5 (141.0–238.0)	334.2 (± 208.9)	377.5 (116.0–501.0)	-1.69	0.07
CD19+ B lymphocytes	142.7 (± 54.2)	142.0 (129.0–152.0)	184.5 (± 155.1)	144.5 (78.0–184.0)	-0.67	0.26
CD4/CD8 ratio	3.3 (± 2.3)	3.0 (1.0–5.0)	2.2 (± 1.0)	2.0 (2.0–2.0)	1.78	0.07

HIPEC: Hyperthermic intraperitoneal chemotherapy.